1.Disease overview: Hepatic hemangioma is very common and is the most common benign tumor of the liver, with an incidence of 4%-7%. Hepatic hemangioma is divided into capillary hemangioma and cavernous hemangioma. The former occurs in young children and is often multiple and small. The latter is common in middle-aged patients and is mostly solitary or multiple. The tumor is usually more than 3 cm in diameter and can even be large enough to occupy the entire liver. Hepatic hemangiomas are slow growing and often last for more than a few years. 50%-70% of patients are clinically asymptomatic and are only detected during physical examination or ultrasound or CT examinations for other reasons. For a few tumors larger than 5cm, patients may experience compression symptoms, mainly upper abdominal discomfort. 2.Diagnostic points: The diagnosis of hepatic cavernous hemangioma mainly relies on imaging examination. Hepatic cavernous hemangioma has its typical imaging manifestations in ultrasound, CT, MRI and angiography, so the diagnosis is not difficult. However, for small or atypical hepatic hemangioma, it should be distinguished from hepatocellular carcinoma and other intrahepatic diseases, which mainly relies on comprehensive imaging and laboratory tests. Generally, AFP examination is required for hepatocellular carcinoma blood release index. 3.Treatment options: Most of the small hepatic cavernous hemangiomas without clinical symptoms can be left untreated. Larger hepatic cavernous hemangiomas that compress adjacent organs and/or liver envelope and cause obvious compression symptoms and/or pain, as well as hemangioma rupture and bleeding can be treated by surgery or interventional therapy. The former is very traumatic, and if the lesion is small and deep, the sacrifice of more normal liver in order to remove a benign lesion is not worth the loss. Therefore, interventional treatment is preferable. The main interventional treatment methods for hepatic cavernous hemangioma are: percutaneous puncture femoral artery cannulation hepatic artery embolization (TAE) and percutaneous puncture intra-tumor injection method. The former cannulation and embolization techniques and methods are basically the same as those for hepatocellular carcinoma. The latter method can be used to inject drugs into the tumor under the guidance of B-ultrasound and CT, and multiple injections are used to fill the whole tumor with drugs to achieve the treatment purpose. Most of the embolic drugs used are super-liquid iodized oil and/or PVA embolic particles and anhydrous alcohol, and most of the vascularizing drugs are Pingyangmycin. There are no absolute contraindications for hepatic cavernous hemangioma interventions, as long as the patient does not have bleeding tendency and coagulation dysfunction and serious cardiac and renal dysfunction and liver dysfunction, and there is no obvious history of contrast allergy, they can generally be performed. Severe arteriovenous fistula or arteriovenous-portal fistula is a relative contraindication. 4. Complications and their management: Before embolization, detailed angiography should be performed to fully understand the blood flow of the tumor, avoid the gallbladder artery, and if necessary, a balloon catheter should be used to avoid the regurgitation of the embolic agent. Postoperative adverse reactions are mainly hepatic distension, fever and transient liver function injury, which can be solved by general drug prevention. 5.Health care and rehabilitation: Hepatic cavernous hemangioma is a benign tumor, if the tumor is small (less than 2cm) and asymptomatic, no treatment can be done, and the patient only needs regular review. For larger hepatic cavernous hemangioma, some patients may experience pain in the liver area for a short period of time after interventional treatment, but generally no special treatment is needed. 6.Following up after interventional treatment: postoperative liver protection treatment should be strengthened. Generally, the liver CT scan and enhancement scan should be reviewed 6 months after the intervention, and if there is still residual tumor, additional embolization therapy can be performed again as appropriate.